Shares of Shire PLC (ADR) (NASDAQ:SHPG) ended Wednesday session in red amid volatile trading. The shares closed down -0.74 points or -0.41% at $178.95 with 879,799 shares getting traded. Post opening the session at $178.58, the shares hit an intraday low of $178.25 and an intraday high of $180.06 and the price vacillated in this range throughout the day. The company has a market cap of $53.35 billion and the numbers of outstanding shares have been calculated to be 906.90 million shares.
Shire PLC (ADR) (SHPG) announced that the European Commission (EC) has granted Marketing Authorization of ONIVYDE® (pegylated liposomal irinotecan hydrochloride trihydrate), also known as nal-IRI or MM-398, for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine-based therapy. ONIVYDE is the first and only approved treatment option for this patient population.
With this approval, Shire is authorized to market ONIVYDE in the 28 Member States of the European Union (EU), as well as in Iceland, Liechtenstein and Norway. ONIVYDE was previously approved in the U.S. by the Food and Drug Administration (FDA), in October 2015.
“As the only treatment for metastatic pancreatic cancer following gemcitabine-based therapy that may improve patient survival, ONIVYDE is the first innovation that offers the potential to improve outcomes for this challenging patient population,” said Philip J. Vickers, Ph.D., Global Head of Research and Development at Shire. “The approval of ONIVYDE marks a significant step forward in Shire’s focus to develop and commercialize treatments that represent the most promising science in oncology.”
Shares of Amgen, Inc. (NASDAQ:AMGN) ended Wednesday session in green amid volatile trading. The shares closed up +1.10 points or 0.69% at $158.99 with 2.72 million shares getting traded. Post opening the session at $158.68, the shares hit an intraday low of $158.03 and an intraday high of $160.05 and the price vacillated in this range throughout the day. The company has a market cap of $118.33 billion and the numbers of outstanding shares have been calculated to be 748.36 million shares.
Amgen, Inc. (AMGN) announced that it will report its third quarter financial results on Thursday, Oct. 27, 2016, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen’s senior management team.
Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.